List of Contents

Lyophilized Injectable Drugs Market Size, Share, and Trends 2024 to 2033

Lyophilized Injectable Drug Market (By Drug Type: Anti-infective, Anti-neoplastic, Diuretics, Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, Corticosteroids, Others; By Indication: Oncology, Autoimmune Diseases, Hormonal Disorders, Respiratory Diseases, Gastrointestinal Disorders, Dermatological Disorders, Ophthalmic Diseases, Others; By Delivery Type; By Packaging; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : April 2024
  • Report Code : 4180
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Lyophilized Injectable Drug Market 

5.1. COVID-19 Landscape: Lyophilized Injectable Drug Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Lyophilized Injectable Drug Market, By Drug Type

8.1. Lyophilized Injectable Drug Market Revenue and Volume, by Drug Type, 2024-2033

8.1.1. Anti-infective

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Anti-neoplastic

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Diuretics

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Proton Pump Inhibitor

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Anesthetic

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Anticoagulant

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. NSAID’s

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

8.1.8. Corticosteroids

8.1.8.1. Market Revenue and Volume Forecast (2021-2033)

8.1.9. Others

8.1.9.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Lyophilized Injectable Drug Market, By Indication

9.1. Lyophilized Injectable Drug Market Revenue and Volume, by Indication, 2024-2033

9.1.1. Oncology

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Autoimmune Diseases

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Hormonal Disorders

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Respiratory Diseases

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Gastrointestinal Disorders

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Dermatological Disorders

9.1.6.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. Ophthalmic Diseases

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

9.1.8. Others

9.1.8.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Lyophilized Injectable Drug Market, By Delivery Type 

10.1. Lyophilized Injectable Drug Market Revenue and Volume, by Delivery Type, 2024-2033

10.1.1. Prefilled Diluent Syringes

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Multi-step Devices

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Lyophilized Injectable Drug Market, By Packaging

11.1. Lyophilized Injectable Drug Market Revenue and Volume, by Packaging, 2024-2033

11.1.1. Vials

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Cartridges

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Prefilled Devices

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Lyophilized Injectable Drug Market, By Distribution Channel

12.1. Lyophilized Injectable Drug Market Revenue and Volume, by Distribution Channel, 2024-2033

12.1.1. Hospital Pharmacy

12.1.1.1. Market Revenue and Volume Forecast (2021-2033)

12.1.2. Retail Pharmacy

12.1.2.1. Market Revenue and Volume Forecast (2021-2033)

12.1.3. Online Pharmacy

12.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 13. Global Lyophilized Injectable Drug Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.1.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.1.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.6.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.1.6.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.1.6.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.1.7.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.1.7.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.1.7.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.2.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.2.4. Market Revenue and Volume Forecast, by Packaging (2021-2033) 

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.6.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.2.6.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.2.7. Market Revenue and Volume Forecast, by Packaging (2021-2033) 

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033) 

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.9.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.2.9.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.2.10. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.12.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.2.12.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.2.12.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.2.14.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.2.14.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.2.14.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.3.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.3.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.6.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.3.6.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.3.6.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.8.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.3.8.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.3.8.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.10.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.3.10.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.3.10.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.3.11.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.3.11.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.3.11.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.4.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.4.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.6.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.4.6.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.4.6.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.8.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.4.8.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.4.8.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.10.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.4.10.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.4.10.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.4.11.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.4.11.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.4.11.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.5.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.5.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.5.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.5.6.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.5.6.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.5.6.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type (2021-2033)

13.5.8.2. Market Revenue and Volume Forecast, by Indication (2021-2033)

13.5.8.3. Market Revenue and Volume Forecast, by Delivery Type (2021-2033)

13.5.8.4. Market Revenue and Volume Forecast, by Packaging (2021-2033)

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 14. Company Profiles

14.1. Pfizer Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Novartis AG

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Roche Holding AG

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Johnson & Johnson

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Sanofi S.A.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Amgen Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. AbbVie Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Merck & Co., Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Eli Lilly and Company

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. AstraZeneca PLC

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global lyophilized injectable drug market size is expected to increase USD 578.47 billion by 2033 from USD 247.97 billion in 2023.

The global lyophilized injectable drug market will register growth rate of 8.84% between 2024 and 2033.

The major players operating in the lyophilized injectable drug market are Pfizer Inc., Novartis AG, Roche Holding AG, Johnson & Johnson, Sanofi S.A., Amgen Inc., AbbVie Inc., Merck & Co., Inc., Eli Lilly and Company, AstraZeneca PLC, Bristol Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Celgene Corporation, Novo Nordisk A/S, Vertex Pharmaceuticals Incorporated, Takeda Pharmaceutical Company Limited, and Others.

The driving factors of the lyophilized injectable drug market are the wide range of adoption across the globe and rising use of orphan drugs.

North America region will lead the global lyophilized injectable drug market during the forecast period 2024 to 2033.

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Plan your call and get expert insights!

Schedule a Meeting Schedule a Meeting

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us